ClinicalTrials.gg

Program

nkt5097 cdk2

A development code. Also written as “NKT5097 CDK2/CDK4 dual degrader”.

Its studies are mostly in Triple Negative Breast Neoplasms, led by NiKang Therapeutics.

Furthest: phase 1, since May 28, 20251 company-led study, 1 open or runningNext primary completion: Jul 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NiKang Therapeutics11 open or runningphase 1since May 28, 2025May 28, 2025Jul 31, 2027phase 1 · NCT07029399

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 28, 2025First study: phase 1 study in Triple Negative Breast NeoplasmsFirst studyNCT07029399 · 361 planned · United States

Ahead

  1. Jul 31, 2027Primary completion: phase 1 study in Triple Negative Breast NeoplasmsNCT07029399

TargetBeta

CDK2 →CDK4 →read by rule
“This First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of NKT5097, a novel dual protein degrader of CDK2 and CDK4, is split into 3 Parts:”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
culmerciclibSino Biopharmaceuticalphase 311
vustanaciclibregor-pharmaceuticals-incphase 23
CG-7321rulechengdu-cynogen-bio-pharmaceutical-tech-co-ltdphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07029399Triple Negative Breast Neoplasms · United States1RecruitingJul 31, 2027361

How it is read

Names in the registry

  • “NKT5097 CDK2/CDK4 dual degrader”, 1 entry

Codes read as this program: NKT5097.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.